EUVIMEDOpdag EUVIMED
Vergleichsstudie

Comparison of Mycophenolate Dosing Strategies in Pediatric Heart Transplant

Dawn Y Nguyen iD, Anastacia Serluco iD, Justin K Chen iD, Gwen Nance iD, Zeling He iD, Arene Butto iD

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70422 ↗

At a glance

Vergleichsstudie in Clinical Transplantation, 2026. Written by Dawn Y Nguyen and 5 co-authors. Institution: Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Major MEDLINE topics: Heart Transplantation, Mycophenolic Acid, Immunosuppressive Agents, Graft Rejection. 16 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Mycophenolic acid (MPA) is a common immunosuppressant used in children post‐orthotopic heart transplant (OHT). Multiple MPA dosing strategies exist, with limited reports of comparisons between dosing strategies and patient outcomes.

Methods

We performed a retrospective review of heart transplant recipients ≤ 21 years from 2014 to 2022, comparing dose concordance and clinical outcomes of weight‐based mycophenolate dosing (15 mg/kg/dose every 12 h) to body surface area (BSA)‐based dosing (600 mg/m 2 /dose every 12 h).

Results

We analyzed 109 patients total (56% in the BSA‐based cohort and 44% in the weight‐based cohort). The BSA‐based cohort received a higher total milligram dose (480 (IQR 200–563) vs. 636 (IQR 320–1000), p = 0.005), mg/kg dose (14.5 (IQR 13.7–16.1) vs. 20.7 (IQR 16.4–25.8), p < 0.001) and mg/m 2 dose (382 (IQR 333–470) vs. 596 (IQR 572–612), p < 0.001) compared to the weight‐based cohort. The BSA‐based cohort experienced a lower hazard of rejection (HR 0.2, 95% CI 0.1–0.4 vs. weight‐based) and a greater hazard for overall infection (HR 2.2, 95% CI 1.2–3.9). There was no significant difference in 1‐year post‐transplant mortality and incidence of post‐transplant lymphoproliferative disorder (PTLD).

Conclusions

This study demonstrates the discordance between two common mycophenolate dosing strategies (1200 mg/m 2 /day vs. 30 mg/kg/day) and its resultant impact on pediatric heart transplant‐related outcomes. Further multicenter data would be useful to elucidate the impact on post‐heart transplant morbidity and mortality.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationMycophenolic AcidImmunosuppressive AgentsGraft RejectionPostoperative ComplicationsHumansRetrospective StudiesMaleFemaleChildFollow-Up StudiesPrognosisAdolescentChild, PreschoolGraft SurvivalRisk FactorsInfantYoung AdultSurvival Rate

Author keywords

antiproliferative agent: mycophenolate mofetil (MMF)antiproliferative agent: mycophenolate sodiumenteric coatedheart (allograft) function/dysfunctionimmunosuppressant

Substances

Mycophenolic AcidImmunosuppressive Agents

Authors and institutions

  • Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

ORCID profiles: Dawn Y Nguyen, Anastacia Serluco, Justin K Chen, Gwen Nance, Zeling He, Arene Butto

Cite

APA

Nguyen, D. Y., Serluco, A., Chen, J. K., Nance, G., He, Z., & Butto, A. (2026). Comparison of Mycophenolate Dosing Strategies in Pediatric Heart Transplant. Clinical Transplantation. https://doi.org/10.1111/ctr.70422

Vancouver

Nguyen DY, Serluco A, Chen JK, Nance G, He Z, Butto A. Comparison of Mycophenolate Dosing Strategies in Pediatric Heart Transplant. Clinical Transplantation. 2026. doi:10.1111/ctr.70422

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Dawn Y and Serluco, Anastacia and Chen, Justin K and Nance, Gwen and He, Zeling and Butto, Arene},
  title = {Comparison of Mycophenolate Dosing Strategies in Pediatric Heart Transplant},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70422}
}
Start for free →